Report Categories

According to our (Global Info Research) latest study, the global Gene Therapy Products market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

USD3480.00

Add To Cart

AAV-based gene therapy products utilize adeno-associated virus (AAV) vectors as delivery vehicles to transfer therapeutic genes into target cells for the treatment of various genetic disorders and diseases. AAV vectors are non-pathogenic viruses that can efficiently infect a wide range of cells and have a low immunogenicity profile, making them suitable candidates for gene therapy applications. In AAV-based gene therapy, the therapeutic gene of interest is inserted into the AAV vector's genome, and the vector is then administered to the patient, typically via intravenous injection or direct injection into the affected tissue. Once inside the target cells, the AAV vector delivers the therapeutic gene, allowing it to be expressed and produce the desired therapeutic protein. AAV-based gene therapy products hold significant promise for the treatment of inherited genetic disorders, as well as acquired diseases such as certain types of cancer and neurodegenerative disorders, offering potential long-term therapeutic benefits with a single administration.

USD4480.00

Add To Cart

AAV-based gene therapy products utilize adeno-associated virus (AAV) vectors as delivery vehicles to transfer therapeutic genes into target cells for the treatment of various genetic disorders and diseases. AAV vectors are non-pathogenic viruses that can efficiently infect a wide range of cells and have a low immunogenicity profile, making them suitable candidates for gene therapy applications. In AAV-based gene therapy, the therapeutic gene of interest is inserted into the AAV vector's genome, and the vector is then administered to the patient, typically via intravenous injection or direct injection into the affected tissue. Once inside the target cells, the AAV vector delivers the therapeutic gene, allowing it to be expressed and produce the desired therapeutic protein. AAV-based gene therapy products hold significant promise for the treatment of inherited genetic disorders, as well as acquired diseases such as certain types of cancer and neurodegenerative disorders, offering potential long-term therapeutic benefits with a single administration.

USD3480.00

Add To Cart

LV-based cell and gene therapy products refer to therapeutic products that utilize lentiviral vectors (LV) as a delivery system for introducing genetic material into target cells. Lentiviral vectors are commonly used in gene therapy to transfer genes into cells for the treatment of genetic disorders, cancer, and other diseases.

USD4480.00

Add To Cart

LV-based cell and gene therapy products refer to therapeutic products that utilize lentiviral vectors (LV) as a delivery system for introducing genetic material into target cells. Lentiviral vectors are commonly used in gene therapy to transfer genes into cells for the treatment of genetic disorders, cancer, and other diseases.

USD3480.00

Add To Cart

The global Gene Therapy Products market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

USD4480.00

Add To Cart

According to our (Global Info Research) latest study, the global Gene Therapy Products market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

USD3480.00

Add To Cart